Helus Pharma Inc.
HELPHealthcare|Medical - Pharmaceuticals|CA
$8.96
+0.57 (+6.79%)
DCF Value
$3.20
Financials
Financial Snapshot
Market Cap
$555.4M
Enterprise Value
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$183.3M
Cash & Investments
$166.2M
Net Cash
$166.2M
Free Cash Flow (TTM)
-$154.6M
Operating CF (TTM)
-$153.0M
Debt/Equity
—
Cash Runway & Burn Rate
Cash on Hand
$166.2M
Quarterly Burn
$38.2M
Monthly Burn
$12.7M
Est. Runway
~4.3 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $432.8K | $433.1K | $314.3K | $1.5M | $64.0M | $53.6M | $16.6M | $209.0M | $135.0M | $157.8M | $166.2M | |
| Operating Cash Flow | $2.8K | -$237.0K | -$83.8K | -$1.4K | -$19.0M | -$45.2M | -$47.4M | -$68.9M | -$101.3M | -$132.4M | -$153.0M | |
| Free Cash Flow | -$7.2K | -$247.0K | -$118.8K | -$1.4K | -$19.3M | -$45.7M | -$50.7M | -$69.6M | -$103.3M | -$133.8M | -$154.6M | |
| Capital Expenditure | -$10.0K | -$10.0K | -$35.0K | $0.00 | -$231.0K | -$520.0K | -$3.3M | -$710.0K | -$2.0M | -$1.4M | -$1.6M | |
| Financing Cash Flow | $440.0K | $247.3K | $0.00 | $5.3K | $82.7M | $35.8M | $13.6M | $254.5M | $20.2M | $197.0M | $188.4M |
R&D Spending
R&D (TTM)
$109.0M
R&D Intensity
—
R&D Growth vs Prior
+26.7%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $864.0K | $167.8K | $251.0K | $0.00 | $472.3K | -$44.7M | $0.00 | |
| R&D Expense | $0.00 | $0.00 | $0.00 | $321.6K | $3.3M | $17.6M | $25.5M | $32.4M | $54.9M | $86.0M | $109.0M | |
| R&D % of Revenue | — | — | — | — | 381.9% | 10482.8% | 10155.2% | — | 11626.8% | -192.5% | — | |
| SG&A | $127.2K | $189.9K | $80.5K | $1.6M | $27.4M | $46.3M | $26.0M | $46.5M | $88.2M | $56.0M | $68.1M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $864.0K | $167.8K | $251.0K | $0.00 | $472.3K | -$44.7M | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.2M | $167.8K | $251.0K | $0.00 | $472.3K | $119.2K | $30.2K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$311.0K | $0.00 | $0.00 | $0.00 | $0.00 | -$44.8M | -$30.2K | |
| R&D | $0.00 | $0.00 | $0.00 | $321.6K | $3.3M | $17.6M | $25.5M | $32.4M | $54.9M | $86.0M | $109.0M | |
| SG&A | $127.2K | $189.9K | $80.5K | $1.6M | $27.4M | $46.3M | $26.0M | $46.5M | $88.2M | $56.0M | $68.1M | |
| Operating Income | -$127.0K | -$189.9K | -$80.5K | -$2.0M | -$31.0M | -$63.8M | -$51.5M | -$78.8M | -$143.1M | -$141.7M | -$177.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $10.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$127.0K | -$220.8K | -$101.0K | -$1.9M | -$32.2M | -$67.8M | -$47.7M | -$78.1M | -$113.6M | -$57.7M | -$183.3M | |
| Net Income | -$127.0K | -$220.8K | -$101.0K | -$1.9M | -$32.2M | -$67.6M | -$47.5M | -$78.1M | -$113.1M | -$147.1M | -$183.3M | |
| EPS (Diluted) | -0.35 | -0.69 | -0.28 | -1.82 | -12.24 | -15.36 | -9.74 | -9.41 | -5.59 | -4.23 | -5.51 | |
| EBITDA | -$127.0K | -$220.8K | -$80.9K | -$400.00 | -$31.0M | -$63.7M | -$51.3M | -$78.4M | -$142.7M | -$141.6M | -$177.0M | |
| Shares Out. (M) | 0.36 | 0.32 | 0.37 | 1.32 | 2.63 | 4.40 | 4.88 | 20.00 | 20.22 | 34.80 | 52.32 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $432.8K | $433.1K | $314.3K | $1.5M | $64.0M | $53.6M | $16.6M | $209.0M | $135.0M | $157.8M | $166.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $433.1K | $436.2K | $318.4K | $1.6M | $66.5M | $58.4M | $23.2M | $218.5M | $166.0M | $185.1M | $192.5M | |
| Total Assets | $443.1K | $456.2K | $408.4K | $1.7M | $92.1M | $84.1M | $53.9M | $302.0M | $258.6M | $252.0M | $259.3M | |
| Total Current Liabilities | $150.3K | $15.9K | $13.7K | $263.0K | $4.9M | $7.9M | $5.7M | $10.1M | $21.4M | $19.4M | $17.5M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $150.3K | $15.9K | $13.7K | $263.0K | $6.0M | $7.9M | $5.7M | $10.1M | $21.4M | $19.4M | $17.5M | |
| Stockholders' Equity | $292.8K | $440.3K | $394.7K | $1.4M | $86.1M | $76.2M | $48.2M | $291.9M | $237.2M | $232.2M | $241.8M | |
| Retained Earnings | -$127.2K | -$348.2K | -$448.8K | -$810.0K | -$33.0M | -$100.7M | -$148.2M | -$226.2M | -$339.4M | -$390.8M | -$436.8M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.8K | -$237.0K | -$83.8K | -$1.4K | -$19.0M | -$45.2M | -$47.4M | -$68.9M | -$101.3M | -$132.4M | -$153.0M | |
| Capital Expenditure | -$10.0K | -$10.0K | -$35.0K | $0.00 | -$231.0K | -$520.0K | -$3.3M | -$710.0K | -$2.0M | -$1.4M | -$1.6M | |
| Free Cash Flow | -$7.2K | -$247.0K | -$118.8K | -$1.4K | -$19.3M | -$45.7M | -$50.7M | -$69.6M | -$103.3M | -$133.8M | -$154.6M | |
| Investing Cash Flow | -$10.0K | -$10.0K | -$35.0K | -$170.40 | -$1.2M | -$770.0K | -$3.3M | $6.9M | -$2.0M | -$1.4M | -$1.6M | |
| Financing Cash Flow | $440.0K | $247.3K | $0.00 | $5.3K | $82.7M | $35.8M | $13.6M | $254.5M | $20.2M | $197.0M | $188.4M | |
| Issuance of Stock | $440.0K | $267.3K | $0.00 | $0.00 | $76.2M | $35.8M | $13.6M | $254.7M | $20.5M | $172.8M | $208.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$149.0K | -$290.0K | $24.2M | -$20.2M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $153.60 | $11.6M | $18.0M | $4.7M | $13.9M | $42.9M | $0.00 | $5.0M | |
| Net Change in Cash | $432.8K | $294.00 | -$118.8K | $3.7K | $62.5M | -$10.4M | -$37.0M | $192.4M | -$74.0M | $64.0M | $33.9M |
Dilution Tracker
Shares outstanding grew 1222.2% over 5 years — significant dilution
Shares Outstanding
62M
5-Year Share Growth
+1222.2%
Stock Issuance (TTM)
$208.5M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.36 | 0.32 | 0.37 | 1.32 | 2.63 | 4.40 | 4.88 | 20.00 | 20.22 | 34.80 | 52.32 | |
| Change vs Prior % | — | -11.2% | 14.1% | 260.0% | 100.1% | 67.2% | 10.8% | 309.9% | 1.1% | 72.1% | 50.3% | |
| Stock Issuance | $440.0K | $267.3K | $0.00 | $0.00 | $76.2M | $35.8M | $13.6M | $254.7M | $20.5M | $172.8M | $208.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $153.60 | $11.6M | $18.0M | $4.7M | $13.9M | $42.9M | $0.00 | $5.0M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | -36.0% | 0.0% | 0.0% | — | 0.0% | 100.3% | — | |
| Operating Margin % | — | — | — | — | -3592.0% | -38053.2% | -20523.9% | — | -30310.4% | 317.1% | — | |
| Net Margin % | — | — | — | — | -3729.2% | -40314.1% | -18919.2% | — | -23956.0% | 329.1% | — | |
| EBITDA Margin % | — | — | — | — | -3586.3% | -37953.0% | -20423.9% | — | -30210.4% | 316.8% | — | |
| FCF Margin % | — | — | — | — | -2228.9% | -27257.4% | -20213.9% | — | -21865.9% | 299.4% | — | |
| ROE % | -43.4% | -50.2% | -25.6% | -134.3% | -37.4% | -88.8% | -98.5% | -26.7% | -47.7% | -63.3% | — | |
| ROA % | -28.7% | -48.4% | -24.7% | -113.6% | -35.0% | -80.5% | -88.1% | -25.9% | -43.7% | -58.4% | — | |
| ROIC % | -43.4% | -43.1% | -20.4% | -134.9% | -35.6% | -83.6% | -106.2% | -27.0% | -60.1% | -60.9% | — | |
| R&D / Revenue % | — | — | — | — | 381.9% | 10482.8% | 10155.2% | — | 11626.8% | -192.5% | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -80.6% | 49.6% | -100.0% | 0.0% | -9561.6% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -49.6% | 57.6% | -2326.7% | -1488.3% | -105.7% | 19.3% | -53.0% | -81.6% | 1.0% | |
| Net Income | 0.0% | -73.9% | 54.3% | -1824.8% | -1557.4% | -109.9% | 29.8% | -64.4% | -44.9% | -30.0% | |
| EPS (Diluted) | 0.0% | -97.1% | 59.4% | -550.0% | -572.5% | -25.5% | 36.6% | 3.4% | 40.6% | 24.3% | |
| Operating Cash Flow | 0.0% | -8523.1% | 64.7% | 98.3% | -1373889.0% | -137.6% | -4.9% | -45.3% | -47.0% | -30.7% | |
| Free Cash Flow | 0.0% | -3338.1% | 51.9% | 98.8% | -1390570.1% | -137.4% | -11.0% | -37.2% | -48.3% | -29.6% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 926.1% | 432.9% | 45.0% | 27.0% | 69.7% | 56.7% | |
| SG&A Expense | 0.0% | 49.3% | -57.6% | 1926.7% | 1580.4% | 68.7% | -43.7% | 78.6% | 89.9% | -36.5% | |
| Total Assets | 0.0% | 3.0% | -10.5% | 319.0% | 5283.5% | -8.7% | -35.9% | 460.4% | -14.4% | -2.6% | |
| Book Value / Share | 0.0% | 69.3% | -21.4% | 25.9% | 2306.5% | -47.1% | -42.9% | 47.7% | -19.6% | -43.0% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | -11.2% | 14.1% | 260.0% | 100.1% | 67.2% | 10.8% | 309.9% | 1.1% | 72.1% |
Analyst Estimates & Quality
Altman Z-Score
23.02
Safe
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $31.7M | $10.1M | $145.2M |
| Net Income | -$95.3M | -$91.0M | -$88.6M |
| EPS | $-2.67 | $-2.12 | $-1.61 |
| # Analysts (EPS) | 5 | 3 | 6 |